Overview

Safety, Tolerability and Pharmacokinetics of BI 655066/ABBV-066 (Risankizumab) in Healthy Asian and Caucasian Male Volunteers

Status:
Completed

Trial end date:
2017-06-01

Target enrollment:

Participant gender:

Summary

Safety, tolerability and pharmacokinetics of single dose of BI 655066/ABBV-066 (risankizumab) in healthy Chinese, Japanese and Caucasian male volunteers.

Phase:

Phase 1

Details

Lead Sponsor:

AbbVie

Collaborator:

Boehringer Ingelheim

Treatments:

Antibodies, Monoclonal